1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Stockwatch: The impossible takes a little too long

 
• By Andy Smith

When Tony Blair joined Bill Clinton by satellite link to the White House in 2000 to announce the sequencing of the human genome, biotech stocks soared with the implication that genomics would result in a cure for any disease. Even today, nearly twelve years, recently approved targeted therapies for blood and skin cancers imply that the application of genomic data and molecular biology can result in a treatment for most unmet clinical needs, eventually.

When Tony Blair joined Bill Clinton by satellite link to the White House in 2000 to announce the sequencing of the human genome, biotech stocks soared with the implication that genomics would result in a cure for any disease. Even today, nearly twelve years, recently approved targeted therapies for blood and skin cancers imply that the application of genomic data and molecular biology can result in a treatment for most unmet clinical needs, eventually.

Eventually is however, a long time and while many will recognise it from the school of forward-looking statements, it is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

More from Therapeutic Category

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.